Pfizer and Sangamo Dose First Participant in Phase 3 Study ...

Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first ...

Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of ...

Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics ...

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment. October 7, 2020. The following is an excerpt from a ...

Pfizer Announces Positive Topline Results From Phase 3 Study of ...

In late 2019, Sangamo transferred the manufacturing technology and the Investigational New Drug application to Pfizer. Under the agreement, ...

Sangamo Therapeutics Reports on Pfizer's Announcement of ...

Sangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate.

Pfizer and Sangamo Dose First Participant in Phase 3 Study ...

Pfizer Inc. and Sangamo Therapeutics, Inc. announced that the first participant has been dosed in the Phase 3 AFFINE experimental gene therapy study.

Pfizer, Sangamo Reopen Phase 3 Study of Hemophilia A Gene ...

The FDA placed the AFFINE study on hold in November 2021 after Pfizer and Sangamo had voluntarily paused screening and dosing of participants ...

Pfizer, Sangamo dose first subject in Phase 3 haemophilia A trial ...

Pfizer and its partner Sangamo Therapeutics have dosed the first participant in the Phase 3 AFFINE study, evaluating giroctocogene fitelparvovec, a ...

Giroctocogene fitelparvovec gene therapy for severe hemophilia A

Summary of FVIII activity, ALT, AST, and corticosteroid dosing for individual participants in cohort 4 (giroctocogene fitelparvovec dose: 3 × 1013 vg/kg).

Pfizer, Sangamo dose first participant in phase 3 study of ...

Sangamo is eligible to receive total potential milestone payments of up to $300 million for the development and commercialization of ...

Pfizer, Sangamo Dose First Hemophilia A Patient in Phase 3 with ...

On October 7th, Pfizer and Sangamo therapeutics announced that the first participant had been dosed in the Phase 3 AFFINE study, ...

FDA Signs Off on Restart of Pfizer's Hemophilia Gene Therapy Trial

The company expects to resume dosing in the AFFINE trial in the third quarter of 2022. Overall, the study expects to enroll 63 participants with ...

Pfizer and Sangamo Announce Updated Phase - View PDF

- First patient was dosed in pivotal Phase 3 AFFINE study in October 2020 ... The Phase 1/2 Alta study is an open-label, dose-ranging, multicenter ...

Pfizer Doses First Patient in Study on Hemophilia A Gene Therapy

Pfizer and Sangamo Therapeutics recently announced that the first patient has been dosed in the Phase 3 study of an investigational gene ...

EX-99.1 - SEC.gov

“With the first patient dosed in the Phase 3 AFFINE study in October 2020, we are on track for a readout from this pivotal Phase 3 trial in 2022, which will ...

PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR ...

Dosing resumed on November 10, 2022. All trial sites are anticipated to be active by the end of 2022 and a pivotal readout is expected in the ...

Sangamo Reports Pfizer's Positive Phase 3 Hemophilia A Gene ...

shared promising topline results from the Phase 3 AFFINE trial (NCT04370054). This trial evaluated giroctocogene fitelparvovec, an experimental ...

Months after exiting clinical hold, Pfizer readies to resume dosing in ...

The situation has dragged on longer than anticipated. In February, Sangamo told its investors that Pfizer was aiming to reopen trial sites in ...

Pfizer Doses First Participant in Phase 3 Study for Duchenne ...

Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy ... NEW YORK--(BUSINESS WIRE)-- ...

Form 8-K for Sangamo Therapeutics INC filed 12/13/2023

Giroctocogene fitelparvovec is the subject of the registrational Phase 3 AFFINE clinical trial being conducted by Pfizer. Pfizer expects a ...